Catalog Advanced Search

Search by Categories
Search in Packages
Search by Format
Search by Type
Search by Date Range
Products are filtered by different dates, depending on the combination of live and on-demand components that they contain, and on whether any live components are over or not.
Start
End
Search by Keyword
Sort By
  • Treatment of Opioid Use Disorder: Waiver Qualifying - Chicago, IL - Monday, June 24, 2019

    Product not yet rated Contains 6 Component(s), Medical Credits Offered

    The ASAM Treatment of Opioid Use Disorder Course: Includes Waiver Qualifying Requirements covers all medications and treatments for opioid use disorder, and provides the required education needed to obtain the waiver to prescribe buprenorphine.

    image

        

    image


    Monday, June 24, 2019 | 8:00 am - 12:30 pm

    American Dental Association (Lurie Children’s Hospital Conference Room Space)
    211 East Chicago Avenue
    Chicago, Illinois 60611

    Hosted by ILPQC

    Online Portion Due: Sunday, June 23, 2019

    This course is offered in partnership with the American College of Obstetricians and Gynecologists. The curriculum for this course has been specifically designed for women's health providers.

    Welcome to The ASAM Treatment of Opioid Use Disorder Course online access. This course covers all medications and treatments for opioid use disorder, and provides the required education needed to obtain the waiver to prescribe buprenorphine. ASAM is an approved provider by CSAT/SAMHSA of DATA 2000 training.

    This is an 8-hour blended course combining 4 hours of online learning followed by 4 hours of live learning. The live portion of the course builds off content delivered in the online portion. Course faculty are expecting learners to complete the online portion before attending the live portion. You must complete both portions to receive credit for the course. 

    Getting started: To begin the online portion of the course, please log-in to your right and locate the box that says "View Course." If you do not know your password, or you have forgotten it, select "Forgot Password" and you will be emailed a link to reset your password. Detailed instructions for completing the online portion of the course can be found under the tab titled "Course Instructions."

     If you have any questions, please contact education@ASAM.org.

    1. Locate the box on the right that says “View Course" and click “View Course"
      1. A new window will open with the course. Be sure your pop-up blocker is turned off.
    2. Complete Module 1 and Module 2 (equivalent to four hours of instruction)
    3. You will be required to pass all CME Quizzes with a grade of 70% or higher
    4. Upon completion of both the two online modules and four hours of live, in-person instruction, you will be able to claim CME credit through the ASAM e-Learning Center




    Learning Objectives

    Module 1

    1. Assess patients for the full spectrum of harmful opioid use including misuse and use disorders
    2. Describe the current epidemiologic trends in opioid misuse including overdose and use disorders
    3. Recall opioid use neurobiology as it applies to the development of an opioid use disorder and relapse risk
    4. Summarize the laws regulating office-based opioid treatment including the Drug Addiction Treatment Act of 2000 and the Comprehensive Addiction and Recovery Act of 2016
    5. Summarize the clinical pharmacology, efficacy and safety of methadone, buprenorphine and naltrexone in treating opioid use disorders

    Module 2

    6. Identify and assess patients who are appropriate for treatment with medications for an opioid use disorder in an office-based setting
    7. Describe procedures for setting up office systems to support medication prescribing for opioid use disorders
    8. Describe procedures for initiating, stabilizing, maintaining, monitoring and modifying treatment of patients on buprenorphine or naltrexone

    Module 3

    9. Summarize the assessment and management of patients with psychiatric and medical co-morbidities associated with opioid use disorders
    10. Describe unique issues of treating adolescents, young adults, pregnant and postpartum patients maintained on medications for opioid use disorders
    11. Summarize acute and chronic pain management strategies for patients with an opioid use disorder

    Overall

    12. Apply for a waiver to prescribe buprenorphine to patients with opioid use disorder

    CME Information and Disclosure Listing

    Date of Release: July 2015 

    Approved Through: December 2019

    The American Society of Addiction Medicine (ASAM) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. ASAM has been awarded the highest level of Accreditation with Commendation by the ACCME as a provider of continuing medical education.

    The American Society of Addiction Medicine designates this enduring material for a maximum of AMA PRA Category 1 Credits. Physicians should claim only the credit commensurate with the extent of their participation in the activity. 

    The American Society of Addiction Medicine designates this live activity for a maximum of AMA PRA Category 1 Credits. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    This course has been designated as an approved CME Activity by the American Board of Addiction Medicine (ABAM). Physicians enrolled in the ABAM Maintenance of Certification (MOC) Program can apply a maximum of AMA PRA Category 1 Credit(s) to the CME requirement for Part II: Lifelong Learning and Self-Assessment.

    In accordance with the disclosure policies of ASAM and the ACCME, the effort is made to ensure balance, independence, objectivity, and scientific rigor in all educational activities. These policies include resolving all conflicts of interest between the CME Committee, Planning Committee and faculty, and commercial interests that might otherwise compromise the goal and educational integrity of this activity. All CME Committee, Planning Committee and faculty participating in the activity have disclosed all relevant financial relationships with commercial interests. The CME Committee has reviewed these disclosures and determined that the planning committee and faculty relationships are not inappropriate in the content of their respective presentations and are not inconsistent with the educational goals and integrity of the activity.

    ASAM Treatment of Opioid Use Disorder Course Program Planning Committee

    Name

    Nature of Relevant Financial Relationship

    Commercial Interest

    What was received?

    For what role?

    Dan Alford, MD, MPH, DFASAM, Chair

    None

    Paula J. Lum, MD, MPH, FASAM, Vice Chair

    None

    Edwin Salsitz, MD, DFASAM, Curriculum Director

    None

    Soraya Azari, MD

    None 

    Jill Mattingly, DHSc, MMSc, PA-C

    None

    Debra Newman, PA-C, MPAS, MPH

    None

    Mary McMasters, MD, DFASAMNone

    Yngvild K. Olsen, MD, MPH, DFASAM

    None
    Shawn Ryan, MD, MBA, FASAMAdapt Pharma OrexoConsulting Fee HonorariumContent Expert Speaker
    Kristin Smith, DNP, FNP-C, AAHIVSNone
    Tricia E. Wright, MD, MS, FACOG, FASAMNone

    ASAM CME Committee

    Name

    Nature of Relevant Financial Relationship

    Commercial Interest

    What was received?

    For what role?

    Catherine Friedman, MD, FAPA, DFASAM, Chair

    None

    R. Jeffrey Goldsmith, MD, DLFAPA, DFASAMNone
    Adam J. Gordon, MD, MPH, FACP, DFASAMNone
    Zwaantje Hamming, FNP-C, CARN-APNone

    Herbert L. Malinoff, MD, FACP, DFASAM

    None

    Noel Ilogu, MD, MRCP, DFASAM

    None

    Edwin A. Salsitz, MD, DFASAM

    None

    ASAM Staff and Consultants

    Arlene C. Deverman, MA, CAE, CFRENone

    Marcia Jackson, PhD

    None
    Sandy MetcalfeNone

    ASAM Medical Education Council

    Name

    Nature of Relevant Financial Relationship

    Commercial Interest

    What was received?

    For what role?

    Peter Selby, MBBS, CCFP, FCFP, MHSc, DFASAM, Chair

    Pfizer  Johnson & Johnson Pfizer CanadaGrant funding Consulting Fees Consulting FeesPrincipal  Investigator Consulting Consulting
    Daniel P. Alford, MD, MPH, DFASAMNone
    Michael Fingerhood, MD, FACP, FASAMNone
    Catherine R. Friedman, MD, FAPA, DFASAMNone
    Adam J. Gordon, MD, MPH, FACP, DFASAMNone
    Miriam S. Komaromy, MD, FACP, DFASAMNone
    Edwin A. Salsitz, MD, DFASAMNone
    Mark P. Schwartz, MD, DFASAMNone
    Mark A. Weiner, MD, FASAMNone
    ASAM Staff and Consultants
    Penny S. Mills, MBANone
    Arlene C. Deverman, MA, CAE, CFRENone
    Marcia Jackson, PhDNone
    Dawn C. HowellNone
    Molly S. MazukNone
    Alexandra (Alli) UngerNone
    Jennifer L. ButchartNone


    1. Physicians, Nurse Practitioners, Clinical Nurse Specialists, and Physician Assistants who wish to obtain a waiver to prescribe buprenorphine in office-based treatment of opioid use disorder.
    2. Clinicians and healthcare team members working with physicians who prescribe buprenorphine in office-based treatment of opioid use disorder.

    Overview of Legislation

    Physicians

    The Drug Abuse Treatment Act of 2000 (DATA 2000) specifies training is necessary for physicians to obtain a waiver to engage in office‐based treatment of opioid use disorders using drugs approved by the FDA on Schedules III, IV, and V. This course addresses those requirements using a curriculum approved by CSAT/SAMHSA and ASAM, who is one of the national organizations named in the DATA 2000 legislation as eligible to prepare and administer these courses.

    Nurse Practitioners & Physician Assistants

    On July 22, 2016, President Obama signed the Comprehensive Addiction and Recovery Act (CARA) into law. CARA authorizes qualified NPs and PAs to become waivered to prescribe buprenorphine in office-based settings for patients with Opioid Use Disorder (OUD) for a five-year period expiring in October 2021.    

    To qualify, NPs and PAs must: 

    • Be licensed under state law to prescribe schedule III, IV, or V medications for pain  
    • Complete not less than 24 hours of appropriate education through a qualified provider
    • Through other training or experience, demonstrate the ability to treat and manage OUD  
    • If required by state law, be supervised or work in collaboration with a qualifying physician to prescribe medications for the treatment of OUD

    HHS' announcement on November 16, 2016, enables NPs and PAs to immediately begin taking the 24 hours of required training. For the full HHS announcement, click here.

    NPs and PAs can begin the training immediately by taking the 8-hour buprenorphine course ASAM currently offers or that other stakeholders offer (see below for more information). The remaining 16 hours will have to be completed with one training provider. ASAM is developing multiple 16-hour training course options and formats, including collaborations with:

    The ASAM Treatment of Opioid Use Disorder Course has been made available in part by an unrestricted educational grant from Indivior Inc.


    Please ensure that your state regulations allow you to prescribe buprenorphine and other medications to treat OUD before you apply for the waiver.  Some states may have overriding state legislation that will prevent NPs and PAs from prescribing these medications even if Federal law allows it.

    Apply

    SAMHSA reviews waiver applications within 45 business days of receipt. If approved, you will receive a letter via email that confirms your waiver and includes your prescribing identification number.

    Waiver applications are forwarded to the DEA. DEA regulations require your prescribing identification number to be included on all buprenorphine prescriptions for opioid dependency treatment, along with your regular DEA number.

    If you have not received confirmation of receipt of your application, or if it has been more than 45 business days since submitting it, contact CSAT by email: infobuprenorphine@samhsa.hhs.gov or call 866.287.2728.

    Qualify 

    To qualify for a waiver to treat patients with Opioid Use Disorder, NPs and PAs must: 

    • Be licensed under state law to prescribe schedule III, IV, or V medications for pain
    • Complete no less than 24 hours of appropriate education through a qualified provider
    • Through other training or experience, demonstrate the ability to treat and manage OUD
    • If required by state law, supervision or working in collaboration with a qualifying physician to prescribe medications for the treatment of OUD may be required.

    Apply

    SAMHSA reviews waiver applications within 45 business days of receipt. If approved, you will receive a letter via email that confirms your waiver and includes your prescribing identification number.

    Waiver applications are forwarded to the DEA. DEA regulations require your prescribing identification number to be included on all buprenorphine prescriptions for opioid dependency treatment, along with your regular DEA number.

    If you have not received confirmation of receipt of your application, or if it has been more than 45 business days since submitting it, contact CSAT by email: infobuprenorphine@samhsa.hhs.gov or call 866.287.2728.

  • Treatment of Opioid Use Disorder: Waiver Qualifying - Cincinnati, OH - Saturday, June 22, 2019

    Product not yet rated Contains 6 Component(s), Medical Credits Offered

    The ASAM Treatment of Opioid Use Disorder Course: Includes Waiver Qualifying Requirements covers all medications and treatments for opioid use disorder, and provides the required education needed to obtain the waiver to prescribe buprenorphine.

    image

        

    image


    Saturday, June 22, 2019 | 9:00 am - 1:00 pm

    Mercy Health: Bond Hill Home Office
    Room S144A
    1701 Mercy Health Place
    Cincinnati, OH 45237

    Hosted by BrightView and Mercy Health

    Welcome to The ASAM Treatment of Opioid Use Disorder Course online access. This course covers all medications and treatments for opioid use disorder, and provides the required education needed to obtain the waiver to prescribe buprenorphine. ASAM is an approved provider by CSAT/SAMHSA of DATA 2000 training.

    This is an 8-hour blended course combining 4 hours of live learning followed by 4 hours of online learning. The online portion of the course builds off the content delivered in the live portion. You must complete both portions to receive credit for the course. 

    Getting started: To begin the online portion of the course, please log-in to your right and locate the box that says "View Course." If you do not know your password, or you have forgotten it, select "Forgot Password" and you will be emailed a link to reset your password. Detailed instructions for completing the online portion of the course can be found under the tab titled Course Instructions.

     If you have any questions, please contact education@ASAM.org.

    CME Information and Disclosure Listing

    Date of Release: July 2015 

    Approved Through: December 2019

    The American Society of Addiction Medicine (ASAM) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. ASAM has been awarded the highest level of Accreditation with Commendation by the ACCME as a provider of continuing medical education.

    The American Society of Addiction Medicine designates this live activity for a maximum of AMA PRA Category 1 Credits. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    The American Society of Addiction Medicine designates this enduring material for a maximum of 4 AMA PRA Category 1 Credits. Physicians should claim only the credit commensurate with the extent of their participation in the activity. 

    This program has been reviewed and is approved for a maximum of 8.00 AAPA Category 1 CME credits by the PA Review Panel. Approval is valid for one year from the issue date of 01/01/2018. Participants may submit the post-test at any time during that period.

    This program was planned in accordance with AAPA's CME Standards for Enduring Material Programs and for Commercial Support of Enduring Material Programs.

    This course has been designated as an approved CME Activity by the American Board of Addiction Medicine (ABAM). Physicians enrolled in the ABAM Maintenance of Certification (MOC) Program can apply a maximum of AMA PRA Category 1 Credit(s) to the CME requirement for Part II: Lifelong Learning and Self-Assessment.

    In accordance with the disclosure policies of ASAM and the ACCME, the effort is made to ensure balance, independence, objectivity, and scientific rigor in all educational activities. These policies include resolving all conflicts of interest between the CME Committee, Planning Committee and faculty, and commercial interests that might otherwise compromise the goal and educational integrity of this activity. All CME Committee, Planning Committee and faculty participating in the activity have disclosed all relevant financial relationships with commercial interests. The CME Committee has reviewed these disclosures and determined that the planning committee and faculty relationships are not inappropriate in the content of their respective presentations and are not inconsistent with the educational goals and integrity of the activity.

    ASAM Treatment of Opioid Use Disorder Course Program Planning Committee

    Name

    Nature of Relevant Financial Relationship

    Commercial Interest

    What was received?

    For what role?

    Dan Alford, MD, MPH, DFASAM, Chair

    None

    Paula J. Lum, MD, MPH, FASAM, Vice Chair

    None

    Edwin Salsitz, MD, DFASAM, Curriculum Director

    None

    Soraya Azari, MD

    None 

    Jill Mattingly, DHSc, MMSc, PA-C

    None

    Debra Newman, PA-C, MPAS, MPH

    None

    Mary McMasters, MD, DFASAMNone

    Yngvild K. Olsen, MD, MPH, DFASAM

    None
    Shawn Ryan, MD, MBA, FASAMAdapt Pharma OrexoConsulting Fee HonorariumContent Expert Speaker
    Kristin Smith, DNP, FNP-C, AAHIVSNone
    Tricia E. Wright, MD, MS, FACOG, FASAMNone

    ASAM CME Committee

    Name

    Nature of Relevant Financial Relationship

    Commercial Interest

    What was received?

    For what role?

    Catherine Friedman, MD, FAPA, DFASAM, Chair

    None

    R. Jeffrey Goldsmith, MD, DLFAPA, DFASAMNone
    Adam J. Gordon, MD, MPH, FACP, DFASAMNone
    Zwaantje Hamming, FNP-C, CARN-APNone

    Herbert L. Malinoff, MD, FACP, DFASAM

    None

    Noel Ilogu, MD, MRCP, DFASAM

    None

    Edwin A. Salsitz, MD, DFASAM

    None

    ASAM Staff and Consultants

    Arlene C. Deverman, MA, CAE, CFRENone

    Marcia Jackson, PhD

    None
    Sandy MetcalfeNone

    ASAM Medical Education Council

    Name

    Nature of Relevant Financial Relationship

    Commercial Interest

    What was received?

    For what role?

    Peter Selby, MBBS, CCFP, FCFP, MHSc, DFASAM, Chair

    Pfizer  Johnson & Johnson Pfizer CanadaGrant funding Consulting Fees Consulting FeesPrincipal  Investigator Consulting Consulting
    Daniel P. Alford, MD, MPH, DFASAMNone
    Michael Fingerhood, MD, FACP, FASAMNone
    Catherine R. Friedman, MD, FAPA, DFASAMNone
    Adam J. Gordon, MD, MPH, FACP, DFASAMNone
    Miriam S. Komaromy, MD, FACP, DFASAMNone
    Edwin A. Salsitz, MD, DFASAMNone
    Mark P. Schwartz, MD, DFASAMNone
    Mark A. Weiner, MD, FASAMNone
    ASAM Staff and Consultants
    Penny S. Mills, MBANone
    Arlene C. Deverman, MA, CAE, CFRENone
    Marcia Jackson, PhDNone
    Dawn C. HowellNone
    Molly S. MazukNone
    Alexandra (Alli) UngerNone
    Jennifer L. ButchartNone


    Learning Objectives

    Module 1

    1. Assess patients for the full spectrum of harmful opioid use including misuse and use disorders
    2. Describe the current epidemiologic trends in opioid misuse including overdose and use disorders
    3. Recall opioid use neurobiology as it applies to the development of an opioid use disorder and relapse risk
    4. Summarize the laws regulating office-based opioid treatment including the Drug Addiction Treatment Act of 2000 and the Comprehensive Addiction and Recovery Act of 2016
    5. Summarize the clinical pharmacology, efficacy and safety of methadone, buprenorphine and naltrexone in treating opioid use disorders

    Module 2

    6. Identify and assess patients who are appropriate for treatment with medications for an opioid use disorder in an office-based setting
    7. Describe procedures for setting up office systems to support medication prescribing for opioid use disorders
    8. Describe procedures for initiating, stabilizing, maintaining, monitoring and modifying treatment of patients on buprenorphine or naltrexone

    Module 3

    9. Summarize the assessment and management of patients with psychiatric and medical co-morbidities associated with opioid use disorders
    10. Describe unique issues of treating adolescents, young adults, pregnant and postpartum patients maintained on medications for opioid use disorders
    11. Summarize acute and chronic pain management strategies for patients with an opioid use disorder

    Overall

    12. Apply for a waiver to prescribe buprenorphine to patients with opioid use disorder

    1. Locate the box on the right that says “View Course" and click “View Course"
      1. A new window will open with the course. Be sure your pop-up blocker is turned off.
    2. Complete Module and Module 4
    3. You will be required to pass all Module CME Quizzes with a grade of 70% or higher
    4. Upon completion of both the 4 live hours and 4 online hours of the course, you will be able to claim CME Credit through the ASAM e-Learning Center



    1. Physicians, Nurse Practitioners, and Physician Assistants who wish to obtain a waiver to prescribe buprenorphine in office based treatment of opioid use disorders.
    2. Clinicians and health care team members working with physicians who prescribe buprenorphine in office based treatment of opioid use disorders.

    The ASAM Treatment of Opioid Use Disorder Course has been made available in part by an unrestricted educational grant from Indivior Inc.


    Apply

    SAMHSA reviews waiver applications within 45 business days of receipt. If approved, you will receive a letter via email that confirms your waiver and includes your prescribing identification number.

    Waiver applications are forwarded to the DEA. DEA regulations require your prescribing identification number to be included on all buprenorphine prescriptions for opioid dependency treatment, along with your regular DEA number.

    If you have not received confirmation of receipt of your application, or if it has been more than 45 business days since submitting it, contact CSAT by email: infobuprenorphine@samhsa.hhs.gov or call 866.287.2728.

    Please ensure that your state regulations allow you to prescribe buprenorphine and other medications to treat OUD before you apply for the waiver.  Some states may have overriding state legislation that will prevent NPs and PAs from prescribing these medications even if Federal law allows it.

    Apply

    SAMHSA reviews waiver applications within 45 business days of receipt. If approved, you will receive a letter via email that confirms your waiver and includes your prescribing identification number.

    Waiver applications are forwarded to the DEA. DEA regulations require your prescribing identification number to be included on all buprenorphine prescriptions for opioid dependency treatment, along with your regular DEA number.

    If you have not received confirmation of receipt of your application, or if it has been more than 45 business days since submitting it, contact CSAT by email: infobuprenorphine@samhsa.hhs.gov or call 866.287.2728.

    Qualify 

    To qualify for a waiver to treat patients with Opioid Use Disorder, NPs and PAs must: 

    • Be licensed under state law to prescribe schedule III, IV, or V medications for pain
    • Complete no less than 24 hours of appropriate education through a qualified provider
    • Through other training or experience, demonstrate the ability to treat and manage OUD
    • If required by state law, supervision or working in collaboration with a qualifying physician to prescribe medications for the treatment of OUD may be required.

    Overview of Legislation

    Physicians

    The Drug Abuse Treatment Act of 2000 (DATA 2000) specifies training is necessary for physicians to obtain a waiver to engage in office‐based treatment of opioid use disorders using drugs approved by the FDA on Schedules III, IV, and V. This course addresses those requirements using a curriculum approved by CSAT/SAMHSA and ASAM, who is one of the national organizations named in the DATA 2000 legislation as eligible to prepare and administer these courses.

    Nurse Practitioners & Physician Assistants

    On July 22, 2016, President Obama signed the Comprehensive Addiction and Recovery Act (CARA) into law. CARA authorizes qualified NPs and PAs to become waivered to prescribe buprenorphine in office-based settings for patients with Opioid Use Disorder (OUD) for a five-year period expiring in October 2021.    

    To qualify, NPs and PAs must: 

    • Be licensed under state law to prescribe schedule III, IV, or V medications for pain  
    • Complete not less than 24 hours of appropriate education through a qualified provider
    • Through other training or experience, demonstrate the ability to treat and manage OUD  
    • If required by state law, be supervised or work in collaboration with a qualifying physician to prescribe medications for the treatment of OUD

    HHS' announcement on November 16, 2016, enables NPs and PAs to immediately begin taking the 24 hours of required training. For the full HHS announcement, click here.

    NPs and PAs can begin the training immediately by taking the 8-hour buprenorphine course ASAM currently offers or that other stakeholders offer (see below for more information). The remaining 16 hours will have to be completed with one training provider. ASAM is developing multiple 16-hour training course options and formats, including collaborations with:

  • Treatment of Opioid Use Disorder: Waiver Qualifying - Henrico, VA - Monday, June 10, 2019

    Product not yet rated Contains 3 Component(s), Medical Credits Offered

    The ASAM Treatment of Opioid Use Disorder Course: Includes Waiver Qualifying Requirements covers treating opioid use disorder by using interactive, case-based learning to teach evidence-based practices.

    image

    Host: Virginia Community Health Association

    Monday, June 10, 2019 | 8:00 am - 5:30 pm
    Virginia Community Healthcare Association Conference Center
    3831 Westerre Parkway
    Henrico, VA 23237 

    Cost: FREE

    Welcome to the ASAM Treatment of Opioid Use Disorder Course. Please LOG IN to begin. If you do not know your password, or you have forgotten it, select "Forgot Password" and you will be emailed a link to reset your password.


    This 8-hour live course covers all treatments and medications for opioid use disorder, and is designed for licensed physician assistants, nurse practitioners, and physicians who plan to obtain a waiver to prescribe buprenorphine in office-based treatment of opioid use disorders. Once you have completed the live course, return here to claim CME for the course. If you have any questions, please contact education@ASAM.org.


    Overview of Legislation

    Physician Assistants & Nurse Practitioners

    On July 22, 2016, President Obama signed the Comprehensive Addiction and Recovery Act (CARA) into law. CARA authorizes qualified NPs and PAs to become waivered to prescribe buprenorphine in office-based settings for patients with Opioid Use Disorder (OUD) for a five-year period expiring in October 2021.    

    To qualify, NPs and PAs must: 

    • Be licensed under state law to prescribe schedule III, IV, or V medications for pain  
    • Complete no less than 24 hours of appropriate education through a qualified provider
    • Through other training or experience, demonstrate the ability to treat and manage OUD  
    • If required by state law, be supervised or work in collaboration with a qualifying physician to prescribe medications for the treatment of OUD

    ASAM, AAPA and AANP have formed a collaborative to provide the 24-hour waiver training for physician assistants and nurse practitioners. The three organizations are authorized by statute to provide this training. Educational content has been identified and/or created to satisfy the 24-hour requirement as described in the Comprehensive Addiction and Recovery Act (CARA).

    Please ensure that your state regulations allow you to prescribe buprenorphine and other medications to treat opioid use disorder before you apply for the waiver. Some states may have overriding state legislation that will prevent NPs/PAs from prescribing these medications even if Federal law allows it. Click here to learn more about applying for the waiver.

    This training is divided into two parts of 8 hours and 16 hours. This 8 hour course will satisfy Part 1 and Part 2 can be completed online for free.

    For NPs (CE Credit through AANP): Click Here
    For PAs (AAPA Category 1 CME Credit): Click Here

    Physicians

    The Drug Abuse Treatment Act of 2000 (DATA 2000) specifies training is necessary for physicians to obtain a waiver to engage in office‐based treatment of opioid use disorders using drugs approved by the FDA on Schedules III, IV, and V. This course addresses those requirements using a curriculum approved by CSAT/SAMHSA and ASAM, who is one of the national organizations named in the DATA 2000 legislation as eligible to prepare and administer these courses.



    Click here to view additional resources.

    Upon completion of the live course, you will be able to claim CME Credit through the ASAM e-Learning Center after completing the evaluation module. 

    CME Information and Disclosure Listing

    Date of Release: July 2015
    Approved Through: July 2018

    The American Society of Addiction Medicine (ASAM) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

    The American Society of Addiction Medicine designates this live activity for a maximum of 8 AMA PRA Category 1 Credits. Physicians should claim only the credit commensurate with the extent of their participation in the activity.


    This program has been reviewed and is approved for a maximum of 8.00 AAPA Category 1 CME credits by the PA Review Panel. Approval is valid for one year from the issue date of 01/01/2018. Participants may submit the post-test at any time during that period.

    This program was planned in accordance with AAPA's CME Standards for Enduring Material Programs and for Commercial Support of Enduring Material Programs.



    This course has been designated as an approved CME Activity by the American Board of Addiction Medicine (ABAM). Physicians enrolled in the ABAM Maintenance of Certification (MOC) Program can apply a maximum of 8 AMA PRA Category 1 Credit(s)™ to the CME requirement for Part II: Lifelong Learning and Self-Assessment.

    In accordance with the disclosure policies of ASAM and the ACCME, the effort is made to ensure balance, independence, objectivity, and scientific rigor in all educational activities. These policies include resolving all conflicts of interest between the CME Committee, Planning Committee and faculty, and commercial interests that might otherwise compromise the goal and educational integrity of this activity. All CME Committee, Planning Committee and faculty participating in the activity have disclosed all relevant financial relationships with commercial interests. The CME Committee has reviewed these disclosures and determined that the planning committee and faculty relationships are not inappropriate in the content of their respective presentations and are not inconsistent with the educational goals and integrity of the activity.

    ASAM Treatment of Opioid Use Disorder Course Faculty

    Name

    Nature of Relevant Financial Relationship

    Commercial Interest

    What was received?

    For what role?

    Jill Mattingly, DHSc, MMSc, PA-CNone
    Debra Newman, PA-C, MPAS, MPHNone

    Edwin Salsitz, MD, DFASAM

    None

    R. Corey Waller, MD, MS, DFASAM

    None



    ASAM Treatment of Opioid Use Disorder Course Program Planning Committee


    Name

    Nature of Relevant Financial Relationship

    Commercial Interest

    What was received?

    For what role?

    Dan Alford, MD, MPH, DFASAM, Chair

    None

    Paula J. Lum, MD, MPH, FASAM, Vice Chair

    None

    Edwin Salsitz, MD, DFASAM, Curriculum Director

    None

    Soraya Azari, MD

    None

    Jill Mattingly, DHSc, MMSc, PA-C

    None

    Debra Newman, PA-C, MPAS, MPH

    None

    Mary McMasters, MD, DFASAMNone

    Yngvild K. Olsen, MD, MPH, DFASAM

    None
    Shawn Ryan, MD, MBA, FASAMAdapt Pharma


    Orexo
    Consulting Fee

    Honorarium
    Content Expert

    Speaker
    Kristin Smith, DNP, FNP-C, AAHIVSNone
    Tricia E. Wright, MD, MS, FACOG, FASAMNone


    ASAM CME Committee

    Name

    Nature of Relevant Financial Relationship

    Commercial Interest

    What was received?

    For what role?

    Catherine Friedman, MD, FAPA, DFASAM, Chair

    None

    R. Jeffrey Goldsmith, MD, DLFAPA, DFASAMNone
    Adam J. Gordon, MD, MPH, FACP, DFASAMNone
    Zwaantje Hamming, FNP-C, CARN-APNone

    Herbert L. Malinoff, MD, FACP, DFASAM

    None

    Noel Ilogu, MD, MRCP, DFASAM

    None

    Edwin A. Salsitz, MD, DFASAM

    None

    ASAM Staff and Consultants

    Arlene C. Deverman, MA, CAE, CFRENone

    Marcia Jackson, PhD

    None
    Sandy MetcalfeNone


    ASAM Medical Education Council

    Name

    Nature of Relevant Financial Relationship

    Commercial Interest

    What was received?

    For what role?

    Peter Selby, MBBS, CCFP, FCFP, MHSc, DFASAM, Chair

    Pfizer


    Johnson & Johnson

    Pfizer Canada
    Grant funding

    Consulting Fees

    Consulting Fees
    Principal
    Investigator


    Consulting


    Consulting
    Daniel P. Alford, MD, MPH, DFASAMNone
    Michael Fingerhood, MD, FACP, FASAMNone
    Catherine R. Friedman, MD, FAPA, DFASAMNone
    Adam J. Gordon, MD, MPH, FACP, DFASAMNone
    Miriam S. Komaromy, MD, FACP, DFASAMNone
    Edwin A. Salsitz, MD, DFASAMNone
    Mark P. Schwartz, MD, DFASAMNone
    Mark A. Weiner, MD, FASAMNone
    ASAM Staff and Consultants
    Penny S. Mills, MBANone
    Arlene C. Deverman, MA, CAE, CFRENone
    Marcia Jackson, PhDNone
    Dawn C. HowellNone
    Molly S. MazukNone
    Alexandra (Alli) UngerNone
    Jennifer L. ButchartNone

    At the conclusion of this activity, learners should be able to:

    1. Apply for a waiver to prescribe buprenorphine to their patients with opioid use disorders
    2. Identify and assess patients who are appropriate for treatment with medications
    3. Have specific knowledge concerning the use of medications to manage patients with addiction involving opioid use
    4. Discuss the psychiatric and medical co-morbidities associated with opioid addiction

    Licensed physicians, nurse practitioners, and physician assistants who wish to obtain a waiver to prescribe buprenorphine in office-based treatment of opioid use disorders.



    1. Fill out the survey by clicking the blue “Fill out Survey” button in the box titled “The ASAM Treatment of Opioid Use Disorder Course Live Portion Evaluation” at the end of the training. 

      1. Pro tip: Be sure to scroll down on all Likert Scale questions. There are answers that expand past the size of the survey window

    2. Submit the evaluation. (The next box should activate and the evaluation box should turn green with a white check mark)

    3. Click the button “Claim Medical Credits” in the box titled “CME Certificate”

    4. Choose the type of credit (Physician or Non-physician) and click submit

    5. Click the button “View/Print Certificate” to save or print your certificate
      1. Pro tip: If you ever lose your certificate, you can come back to the e-Learning Center and view it on your Transcript (found on Dashboard)


    Apply

    NPs and PAs who have completed the 24 hours of required training may seek to obtain a DATA 2000 waiver for up to 30 patients by completing the Waiver Notification Form. Effective February 27, 2017, SAMHSA will only accept electronic submissions of the NOI.

    NPs and PAs may send copies of their training certificates to infobuprenorphine@samhsa.hhs.gov or fax them to 301.576.5237. These waiver applications are forwarded to the Drug Enforcement Administration (DEA), which will assign the NP or PA a special identification number. DEA regulations require this number to be included on all buprenorphine prescriptions for opioid dependency treatment, along with the NP’s or PA’s regular DEA registration number.

    SAMHSA shall review waiver applications within 45 days of receipt. If approved, NPs and PAs will receive a letter via email that confirms their waiver and includes their prescribing identification number. 

    Qualify

    To qualify for a waiver to treat patients with Opioid Use Disorder, NPs and PAs must:

    • Be licensed under state law to prescribe schedule III, IV, or V medications for pain
    • Complete no less than 24 hours of appropriate education through a qualified provider
    • Through other training or experience, demonstrate the ability to treat and manage OUD
    • If required by state law, supervision or working in collaboration with a qualifying physician to prescribe medications for the treatment of OUD may be required.

    Please ensure that your state regulations allow you to prescribe buprenorphine and other medications to treat OUD before you apply for the waiver.  Some states may have overriding state legislation that will prevent NPs from prescribing these medications even if Federal law allows it.

    Click here for more information on applying for a waiver to prescribe buprenorphine.

    The ASAM Treatment of Opioid Use Disorder Course has been made available in part by an unrestricted educational grant from Indivior, Inc.

  • Treatment of Opioid Use Disorder: Waiver Qualifying - Cincinnati, OH - Friday, June 7, 2019

    Product not yet rated Contains 6 Component(s), Medical Credits Offered

    The ASAM Treatment of Opioid Use Disorder Course: Includes Waiver Qualifying Requirements covers all medications and treatments for opioid use disorder, and provides the required education needed to obtain the waiver to prescribe buprenorphine.

    image

        

    image


    Friday, June 7, 2019 | 1:00 pm - 5:00 pm

    Mercy Health: Bond Hill Home Office
    Room S144A
    1701 Mercy Health Place
    Cincinnati, OH 45237

    Hosted by BrightView and Mercy Health

    Welcome to The ASAM Treatment of Opioid Use Disorder Course online access. This course covers all medications and treatments for opioid use disorder, and provides the required education needed to obtain the waiver to prescribe buprenorphine. ASAM is an approved provider by CSAT/SAMHSA of DATA 2000 training.

    This is an 8-hour blended course combining 4 hours of live learning followed by 4 hours of online learning. The online portion of the course builds off the content delivered in the live portion. You must complete both portions to receive credit for the course. 

    Getting started: To begin the online portion of the course, please log-in to your right and locate the box that says "View Course." If you do not know your password, or you have forgotten it, select "Forgot Password" and you will be emailed a link to reset your password. Detailed instructions for completing the online portion of the course can be found under the tab titled Course Instructions.

     If you have any questions, please contact education@ASAM.org.

    CME Information and Disclosure Listing

    Date of Release: July 2015 

    Approved Through: December 2019

    The American Society of Addiction Medicine (ASAM) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. ASAM has been awarded the highest level of Accreditation with Commendation by the ACCME as a provider of continuing medical education.

    The American Society of Addiction Medicine designates this live activity for a maximum of AMA PRA Category 1 Credits. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    The American Society of Addiction Medicine designates this enduring material for a maximum of 4 AMA PRA Category 1 Credits. Physicians should claim only the credit commensurate with the extent of their participation in the activity. 

    This program has been reviewed and is approved for a maximum of 8.00 AAPA Category 1 CME credits by the PA Review Panel. Approval is valid for one year from the issue date of 01/01/2018. Participants may submit the post-test at any time during that period.

    This program was planned in accordance with AAPA's CME Standards for Enduring Material Programs and for Commercial Support of Enduring Material Programs.

    This course has been designated as an approved CME Activity by the American Board of Addiction Medicine (ABAM). Physicians enrolled in the ABAM Maintenance of Certification (MOC) Program can apply a maximum of AMA PRA Category 1 Credit(s) to the CME requirement for Part II: Lifelong Learning and Self-Assessment.

    In accordance with the disclosure policies of ASAM and the ACCME, the effort is made to ensure balance, independence, objectivity, and scientific rigor in all educational activities. These policies include resolving all conflicts of interest between the CME Committee, Planning Committee and faculty, and commercial interests that might otherwise compromise the goal and educational integrity of this activity. All CME Committee, Planning Committee and faculty participating in the activity have disclosed all relevant financial relationships with commercial interests. The CME Committee has reviewed these disclosures and determined that the planning committee and faculty relationships are not inappropriate in the content of their respective presentations and are not inconsistent with the educational goals and integrity of the activity.

    ASAM Treatment of Opioid Use Disorder Course Program Planning Committee

    Name

    Nature of Relevant Financial Relationship

    Commercial Interest

    What was received?

    For what role?

    Dan Alford, MD, MPH, DFASAM, Chair

    None

    Paula J. Lum, MD, MPH, FASAM, Vice Chair

    None

    Edwin Salsitz, MD, DFASAM, Curriculum Director

    None

    Soraya Azari, MD

    None 

    Jill Mattingly, DHSc, MMSc, PA-C

    None

    Debra Newman, PA-C, MPAS, MPH

    None

    Mary McMasters, MD, DFASAMNone

    Yngvild K. Olsen, MD, MPH, DFASAM

    None
    Shawn Ryan, MD, MBA, FASAMAdapt Pharma OrexoConsulting Fee HonorariumContent Expert Speaker
    Kristin Smith, DNP, FNP-C, AAHIVSNone
    Tricia E. Wright, MD, MS, FACOG, FASAMNone

    ASAM CME Committee

    Name

    Nature of Relevant Financial Relationship

    Commercial Interest

    What was received?

    For what role?

    Catherine Friedman, MD, FAPA, DFASAM, Chair

    None

    R. Jeffrey Goldsmith, MD, DLFAPA, DFASAMNone
    Adam J. Gordon, MD, MPH, FACP, DFASAMNone
    Zwaantje Hamming, FNP-C, CARN-APNone

    Herbert L. Malinoff, MD, FACP, DFASAM

    None

    Noel Ilogu, MD, MRCP, DFASAM

    None

    Edwin A. Salsitz, MD, DFASAM

    None

    ASAM Staff and Consultants

    Arlene C. Deverman, MA, CAE, CFRENone

    Marcia Jackson, PhD

    None
    Sandy MetcalfeNone

    ASAM Medical Education Council

    Name

    Nature of Relevant Financial Relationship

    Commercial Interest

    What was received?

    For what role?

    Peter Selby, MBBS, CCFP, FCFP, MHSc, DFASAM, Chair

    Pfizer  Johnson & Johnson Pfizer CanadaGrant funding Consulting Fees Consulting FeesPrincipal  Investigator Consulting Consulting
    Daniel P. Alford, MD, MPH, DFASAMNone
    Michael Fingerhood, MD, FACP, FASAMNone
    Catherine R. Friedman, MD, FAPA, DFASAMNone
    Adam J. Gordon, MD, MPH, FACP, DFASAMNone
    Miriam S. Komaromy, MD, FACP, DFASAMNone
    Edwin A. Salsitz, MD, DFASAMNone
    Mark P. Schwartz, MD, DFASAMNone
    Mark A. Weiner, MD, FASAMNone
    ASAM Staff and Consultants
    Penny S. Mills, MBANone
    Arlene C. Deverman, MA, CAE, CFRENone
    Marcia Jackson, PhDNone
    Dawn C. HowellNone
    Molly S. MazukNone
    Alexandra (Alli) UngerNone
    Jennifer L. ButchartNone


    Learning Objectives

    Module 1

    1. Assess patients for the full spectrum of harmful opioid use including misuse and use disorders
    2. Describe the current epidemiologic trends in opioid misuse including overdose and use disorders
    3. Recall opioid use neurobiology as it applies to the development of an opioid use disorder and relapse risk
    4. Summarize the laws regulating office-based opioid treatment including the Drug Addiction Treatment Act of 2000 and the Comprehensive Addiction and Recovery Act of 2016
    5. Summarize the clinical pharmacology, efficacy and safety of methadone, buprenorphine and naltrexone in treating opioid use disorders

    Module 2

    6. Identify and assess patients who are appropriate for treatment with medications for an opioid use disorder in an office-based setting
    7. Describe procedures for setting up office systems to support medication prescribing for opioid use disorders
    8. Describe procedures for initiating, stabilizing, maintaining, monitoring and modifying treatment of patients on buprenorphine or naltrexone

    Module 3

    9. Summarize the assessment and management of patients with psychiatric and medical co-morbidities associated with opioid use disorders
    10. Describe unique issues of treating adolescents, young adults, pregnant and postpartum patients maintained on medications for opioid use disorders
    11. Summarize acute and chronic pain management strategies for patients with an opioid use disorder

    Overall

    12. Apply for a waiver to prescribe buprenorphine to patients with opioid use disorder

    1. Locate the box on the right that says “View Course" and click “View Course"
      1. A new window will open with the course. Be sure your pop-up blocker is turned off.
    2. Complete Module and Module 4
    3. You will be required to pass all Module CME Quizzes with a grade of 70% or higher
    4. Upon completion of both the 4 live hours and 4 online hours of the course, you will be able to claim CME Credit through the ASAM e-Learning Center



    1. Physicians, Nurse Practitioners, and Physician Assistants who wish to obtain a waiver to prescribe buprenorphine in office based treatment of opioid use disorders.
    2. Clinicians and health care team members working with physicians who prescribe buprenorphine in office based treatment of opioid use disorders.

    The ASAM Treatment of Opioid Use Disorder Course has been made available in part by an unrestricted educational grant from Indivior Inc.


    Apply

    SAMHSA reviews waiver applications within 45 business days of receipt. If approved, you will receive a letter via email that confirms your waiver and includes your prescribing identification number.

    Waiver applications are forwarded to the DEA. DEA regulations require your prescribing identification number to be included on all buprenorphine prescriptions for opioid dependency treatment, along with your regular DEA number.

    If you have not received confirmation of receipt of your application, or if it has been more than 45 business days since submitting it, contact CSAT by email: infobuprenorphine@samhsa.hhs.gov or call 866.287.2728.

    Please ensure that your state regulations allow you to prescribe buprenorphine and other medications to treat OUD before you apply for the waiver.  Some states may have overriding state legislation that will prevent NPs and PAs from prescribing these medications even if Federal law allows it.

    Apply

    SAMHSA reviews waiver applications within 45 business days of receipt. If approved, you will receive a letter via email that confirms your waiver and includes your prescribing identification number.

    Waiver applications are forwarded to the DEA. DEA regulations require your prescribing identification number to be included on all buprenorphine prescriptions for opioid dependency treatment, along with your regular DEA number.

    If you have not received confirmation of receipt of your application, or if it has been more than 45 business days since submitting it, contact CSAT by email: infobuprenorphine@samhsa.hhs.gov or call 866.287.2728.

    Qualify 

    To qualify for a waiver to treat patients with Opioid Use Disorder, NPs and PAs must: 

    • Be licensed under state law to prescribe schedule III, IV, or V medications for pain
    • Complete no less than 24 hours of appropriate education through a qualified provider
    • Through other training or experience, demonstrate the ability to treat and manage OUD
    • If required by state law, supervision or working in collaboration with a qualifying physician to prescribe medications for the treatment of OUD may be required.

    Overview of Legislation

    Physicians

    The Drug Abuse Treatment Act of 2000 (DATA 2000) specifies training is necessary for physicians to obtain a waiver to engage in office‐based treatment of opioid use disorders using drugs approved by the FDA on Schedules III, IV, and V. This course addresses those requirements using a curriculum approved by CSAT/SAMHSA and ASAM, who is one of the national organizations named in the DATA 2000 legislation as eligible to prepare and administer these courses.

    Nurse Practitioners & Physician Assistants

    On July 22, 2016, President Obama signed the Comprehensive Addiction and Recovery Act (CARA) into law. CARA authorizes qualified NPs and PAs to become waivered to prescribe buprenorphine in office-based settings for patients with Opioid Use Disorder (OUD) for a five-year period expiring in October 2021.    

    To qualify, NPs and PAs must: 

    • Be licensed under state law to prescribe schedule III, IV, or V medications for pain  
    • Complete not less than 24 hours of appropriate education through a qualified provider
    • Through other training or experience, demonstrate the ability to treat and manage OUD  
    • If required by state law, be supervised or work in collaboration with a qualifying physician to prescribe medications for the treatment of OUD

    HHS' announcement on November 16, 2016, enables NPs and PAs to immediately begin taking the 24 hours of required training. For the full HHS announcement, click here.

    NPs and PAs can begin the training immediately by taking the 8-hour buprenorphine course ASAM currently offers or that other stakeholders offer (see below for more information). The remaining 16 hours will have to be completed with one training provider. ASAM is developing multiple 16-hour training course options and formats, including collaborations with:

  • Treatment of Opioid Use Disorder: Waiver Qualifying - Wasilla, AK - Thursday, June 6, 2019

    Product not yet rated Contains 6 Component(s), Medical Credits Offered

    The ASAM Treatment of Opioid Use Disorder Course: Includes Waiver Qualifying Requirements covers all medications and treatments for opioid use disorder, and provides the required education needed to obtain the waiver to prescribe buprenorphine.

    image

        

    image


    Thursday, June 6, 2019 | 9:00 am - 1:30 pm

    Grandview Hotel
    Pioneer Room
    2900 E. Parks Hwy
    Wasilla, AK 99654

    Hosted by Alaska Primary Care Association

    Welcome to The ASAM Treatment of Opioid Use Disorder Course online access. This course covers all medications and treatments for opioid use disorder, and provides the required education needed to obtain the waiver to prescribe buprenorphine. ASAM is an approved provider by CSAT/SAMHSA of DATA 2000 training.

    This is an 8-hour blended course combining 4 hours of live learning followed by 4 hours of online learning. The online portion of the course builds off the content delivered in the live portion. You must complete both portions to receive credit for the course. 

    Getting started: To begin the online portion of the course, please log-in to your right and locate the box that says "View Course." If you do not know your password, or you have forgotten it, select "Forgot Password" and you will be emailed a link to reset your password. Detailed instructions for completing the online portion of the course can be found under the tab titled Course Instructions.

     If you have any questions, please contact education@ASAM.org.

    CME Information and Disclosure Listing

    Date of Release: July 2015 

    Approved Through: December 2019

    The American Society of Addiction Medicine (ASAM) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. ASAM has been awarded the highest level of Accreditation with Commendation by the ACCME as a provider of continuing medical education.

    The American Society of Addiction Medicine designates this live activity for a maximum of AMA PRA Category 1 Credits. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    The American Society of Addiction Medicine designates this enduring material for a maximum of 4 AMA PRA Category 1 Credits. Physicians should claim only the credit commensurate with the extent of their participation in the activity. 

    This program has been reviewed and is approved for a maximum of 8.00 AAPA Category 1 CME credits by the PA Review Panel. Approval is valid for one year from the issue date of 01/01/2018. Participants may submit the post-test at any time during that period.

    This program was planned in accordance with AAPA's CME Standards for Enduring Material Programs and for Commercial Support of Enduring Material Programs.

    This course has been designated as an approved CME Activity by the American Board of Addiction Medicine (ABAM). Physicians enrolled in the ABAM Maintenance of Certification (MOC) Program can apply a maximum of AMA PRA Category 1 Credit(s) to the CME requirement for Part II: Lifelong Learning and Self-Assessment.

    In accordance with the disclosure policies of ASAM and the ACCME, the effort is made to ensure balance, independence, objectivity, and scientific rigor in all educational activities. These policies include resolving all conflicts of interest between the CME Committee, Planning Committee and faculty, and commercial interests that might otherwise compromise the goal and educational integrity of this activity. All CME Committee, Planning Committee and faculty participating in the activity have disclosed all relevant financial relationships with commercial interests. The CME Committee has reviewed these disclosures and determined that the planning committee and faculty relationships are not inappropriate in the content of their respective presentations and are not inconsistent with the educational goals and integrity of the activity.

    ASAM Treatment of Opioid Use Disorder Course Program Planning Committee

    Name

    Nature of Relevant Financial Relationship

    Commercial Interest

    What was received?

    For what role?

    Dan Alford, MD, MPH, DFASAM, Chair

    None

    Paula J. Lum, MD, MPH, FASAM, Vice Chair

    None

    Edwin Salsitz, MD, DFASAM, Curriculum Director

    None

    Soraya Azari, MD

    None 

    Jill Mattingly, DHSc, MMSc, PA-C

    None

    Debra Newman, PA-C, MPAS, MPH

    None

    Mary McMasters, MD, DFASAMNone

    Yngvild K. Olsen, MD, MPH, DFASAM

    None
    Shawn Ryan, MD, MBA, FASAMAdapt Pharma OrexoConsulting Fee HonorariumContent Expert Speaker
    Kristin Smith, DNP, FNP-C, AAHIVSNone
    Tricia E. Wright, MD, MS, FACOG, FASAMNone

    ASAM CME Committee

    Name

    Nature of Relevant Financial Relationship

    Commercial Interest

    What was received?

    For what role?

    Catherine Friedman, MD, FAPA, DFASAM, Chair

    None

    R. Jeffrey Goldsmith, MD, DLFAPA, DFASAMNone
    Adam J. Gordon, MD, MPH, FACP, DFASAMNone
    Zwaantje Hamming, FNP-C, CARN-APNone

    Herbert L. Malinoff, MD, FACP, DFASAM

    None

    Noel Ilogu, MD, MRCP, DFASAM

    None

    Edwin A. Salsitz, MD, DFASAM

    None

    ASAM Staff and Consultants

    Arlene C. Deverman, MA, CAE, CFRENone

    Marcia Jackson, PhD

    None
    Sandy MetcalfeNone

    ASAM Medical Education Council

    Name

    Nature of Relevant Financial Relationship

    Commercial Interest

    What was received?

    For what role?

    Peter Selby, MBBS, CCFP, FCFP, MHSc, DFASAM, Chair

    Pfizer  Johnson & Johnson Pfizer CanadaGrant funding Consulting Fees Consulting FeesPrincipal  Investigator Consulting Consulting
    Daniel P. Alford, MD, MPH, DFASAMNone
    Michael Fingerhood, MD, FACP, FASAMNone
    Catherine R. Friedman, MD, FAPA, DFASAMNone
    Adam J. Gordon, MD, MPH, FACP, DFASAMNone
    Miriam S. Komaromy, MD, FACP, DFASAMNone
    Edwin A. Salsitz, MD, DFASAMNone
    Mark P. Schwartz, MD, DFASAMNone
    Mark A. Weiner, MD, FASAMNone
    ASAM Staff and Consultants
    Penny S. Mills, MBANone
    Arlene C. Deverman, MA, CAE, CFRENone
    Marcia Jackson, PhDNone
    Dawn C. HowellNone
    Molly S. MazukNone
    Alexandra (Alli) UngerNone
    Jennifer L. ButchartNone


    Learning Objectives

    Module 1

    1. Assess patients for the full spectrum of harmful opioid use including misuse and use disorders
    2. Describe the current epidemiologic trends in opioid misuse including overdose and use disorders
    3. Recall opioid use neurobiology as it applies to the development of an opioid use disorder and relapse risk
    4. Summarize the laws regulating office-based opioid treatment including the Drug Addiction Treatment Act of 2000 and the Comprehensive Addiction and Recovery Act of 2016
    5. Summarize the clinical pharmacology, efficacy and safety of methadone, buprenorphine and naltrexone in treating opioid use disorders

    Module 2

    6. Identify and assess patients who are appropriate for treatment with medications for an opioid use disorder in an office-based setting
    7. Describe procedures for setting up office systems to support medication prescribing for opioid use disorders
    8. Describe procedures for initiating, stabilizing, maintaining, monitoring and modifying treatment of patients on buprenorphine or naltrexone

    Module 3

    9. Summarize the assessment and management of patients with psychiatric and medical co-morbidities associated with opioid use disorders
    10. Describe unique issues of treating adolescents, young adults, pregnant and postpartum patients maintained on medications for opioid use disorders
    11. Summarize acute and chronic pain management strategies for patients with an opioid use disorder

    Overall

    12. Apply for a waiver to prescribe buprenorphine to patients with opioid use disorder

    1. Locate the box on the right that says “View Course" and click “View Course"
      1. A new window will open with the course. Be sure your pop-up blocker is turned off.
    2. Complete Module and Module 4
    3. You will be required to pass all Module CME Quizzes with a grade of 70% or higher
    4. Upon completion of both the 4 live hours and 4 online hours of the course, you will be able to claim CME Credit through the ASAM e-Learning Center



    1. Physicians, Nurse Practitioners, and Physician Assistants who wish to obtain a waiver to prescribe buprenorphine in office based treatment of opioid use disorders.
    2. Clinicians and health care team members working with physicians who prescribe buprenorphine in office based treatment of opioid use disorders.

    The ASAM Treatment of Opioid Use Disorder Course has been made available in part by an unrestricted educational grant from Indivior Inc.


    Apply

    SAMHSA reviews waiver applications within 45 business days of receipt. If approved, you will receive a letter via email that confirms your waiver and includes your prescribing identification number.

    Waiver applications are forwarded to the DEA. DEA regulations require your prescribing identification number to be included on all buprenorphine prescriptions for opioid dependency treatment, along with your regular DEA number.

    If you have not received confirmation of receipt of your application, or if it has been more than 45 business days since submitting it, contact CSAT by email: infobuprenorphine@samhsa.hhs.gov or call 866.287.2728.

    Please ensure that your state regulations allow you to prescribe buprenorphine and other medications to treat OUD before you apply for the waiver.  Some states may have overriding state legislation that will prevent NPs and PAs from prescribing these medications even if Federal law allows it.

    Apply

    SAMHSA reviews waiver applications within 45 business days of receipt. If approved, you will receive a letter via email that confirms your waiver and includes your prescribing identification number.

    Waiver applications are forwarded to the DEA. DEA regulations require your prescribing identification number to be included on all buprenorphine prescriptions for opioid dependency treatment, along with your regular DEA number.

    If you have not received confirmation of receipt of your application, or if it has been more than 45 business days since submitting it, contact CSAT by email: infobuprenorphine@samhsa.hhs.gov or call 866.287.2728.

    Qualify 

    To qualify for a waiver to treat patients with Opioid Use Disorder, NPs and PAs must: 

    • Be licensed under state law to prescribe schedule III, IV, or V medications for pain
    • Complete no less than 24 hours of appropriate education through a qualified provider
    • Through other training or experience, demonstrate the ability to treat and manage OUD
    • If required by state law, supervision or working in collaboration with a qualifying physician to prescribe medications for the treatment of OUD may be required.

    Overview of Legislation

    Physicians

    The Drug Abuse Treatment Act of 2000 (DATA 2000) specifies training is necessary for physicians to obtain a waiver to engage in office‐based treatment of opioid use disorders using drugs approved by the FDA on Schedules III, IV, and V. This course addresses those requirements using a curriculum approved by CSAT/SAMHSA and ASAM, who is one of the national organizations named in the DATA 2000 legislation as eligible to prepare and administer these courses.

    Nurse Practitioners & Physician Assistants

    On July 22, 2016, President Obama signed the Comprehensive Addiction and Recovery Act (CARA) into law. CARA authorizes qualified NPs and PAs to become waivered to prescribe buprenorphine in office-based settings for patients with Opioid Use Disorder (OUD) for a five-year period expiring in October 2021.    

    To qualify, NPs and PAs must: 

    • Be licensed under state law to prescribe schedule III, IV, or V medications for pain  
    • Complete not less than 24 hours of appropriate education through a qualified provider
    • Through other training or experience, demonstrate the ability to treat and manage OUD  
    • If required by state law, be supervised or work in collaboration with a qualifying physician to prescribe medications for the treatment of OUD

    HHS' announcement on November 16, 2016, enables NPs and PAs to immediately begin taking the 24 hours of required training. For the full HHS announcement, click here.

    NPs and PAs can begin the training immediately by taking the 8-hour buprenorphine course ASAM currently offers or that other stakeholders offer (see below for more information). The remaining 16 hours will have to be completed with one training provider. ASAM is developing multiple 16-hour training course options and formats, including collaborations with:

  • Treatment of Opioid Use Disorder: Waiver Qualifying - Fairbanks, AK - Tuesday, June 4, 2019

    Product not yet rated Contains 6 Component(s), Medical Credits Offered

    The ASAM Treatment of Opioid Use Disorder Course: Includes Waiver Qualifying Requirements covers all medications and treatments for opioid use disorder, and provides the required education needed to obtain the waiver to prescribe buprenorphine.

    image

        

    image


    Tuesday, June 4, 2019 | 12:00 pm - 4:30 pm

    Fountainhead Development
    1501 Queens Way
    Fairbanks, AK 99701

    Hosted by Alaska Primary Care Association

    Welcome to The ASAM Treatment of Opioid Use Disorder Course online access. This course covers all medications and treatments for opioid use disorder, and provides the required education needed to obtain the waiver to prescribe buprenorphine. ASAM is an approved provider by CSAT/SAMHSA of DATA 2000 training.

    This is an 8-hour blended course combining 4 hours of live learning followed by 4 hours of online learning. The online portion of the course builds off the content delivered in the live portion. You must complete both portions to receive credit for the course. 

    Getting started: To begin the online portion of the course, please log-in to your right and locate the box that says "View Course." If you do not know your password, or you have forgotten it, select "Forgot Password" and you will be emailed a link to reset your password. Detailed instructions for completing the online portion of the course can be found under the tab titled Course Instructions.

     If you have any questions, please contact education@ASAM.org.

    CME Information and Disclosure Listing

    Date of Release: July 2015 

    Approved Through: December 2019

    The American Society of Addiction Medicine (ASAM) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. ASAM has been awarded the highest level of Accreditation with Commendation by the ACCME as a provider of continuing medical education.

    The American Society of Addiction Medicine designates this live activity for a maximum of AMA PRA Category 1 Credits. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    The American Society of Addiction Medicine designates this enduring material for a maximum of 4 AMA PRA Category 1 Credits. Physicians should claim only the credit commensurate with the extent of their participation in the activity. 

    This program has been reviewed and is approved for a maximum of 8.00 AAPA Category 1 CME credits by the PA Review Panel. Approval is valid for one year from the issue date of 01/01/2018. Participants may submit the post-test at any time during that period.

    This program was planned in accordance with AAPA's CME Standards for Enduring Material Programs and for Commercial Support of Enduring Material Programs.

    This course has been designated as an approved CME Activity by the American Board of Addiction Medicine (ABAM). Physicians enrolled in the ABAM Maintenance of Certification (MOC) Program can apply a maximum of AMA PRA Category 1 Credit(s) to the CME requirement for Part II: Lifelong Learning and Self-Assessment.

    In accordance with the disclosure policies of ASAM and the ACCME, the effort is made to ensure balance, independence, objectivity, and scientific rigor in all educational activities. These policies include resolving all conflicts of interest between the CME Committee, Planning Committee and faculty, and commercial interests that might otherwise compromise the goal and educational integrity of this activity. All CME Committee, Planning Committee and faculty participating in the activity have disclosed all relevant financial relationships with commercial interests. The CME Committee has reviewed these disclosures and determined that the planning committee and faculty relationships are not inappropriate in the content of their respective presentations and are not inconsistent with the educational goals and integrity of the activity.

    ASAM Treatment of Opioid Use Disorder Course Program Planning Committee

    Name

    Nature of Relevant Financial Relationship

    Commercial Interest

    What was received?

    For what role?

    Dan Alford, MD, MPH, DFASAM, Chair

    None

    Paula J. Lum, MD, MPH, FASAM, Vice Chair

    None

    Edwin Salsitz, MD, DFASAM, Curriculum Director

    None

    Soraya Azari, MD

    None 

    Jill Mattingly, DHSc, MMSc, PA-C

    None

    Debra Newman, PA-C, MPAS, MPH

    None

    Mary McMasters, MD, DFASAMNone

    Yngvild K. Olsen, MD, MPH, DFASAM

    None
    Shawn Ryan, MD, MBA, FASAMAdapt Pharma OrexoConsulting Fee HonorariumContent Expert Speaker
    Kristin Smith, DNP, FNP-C, AAHIVSNone
    Tricia E. Wright, MD, MS, FACOG, FASAMNone

    ASAM CME Committee

    Name

    Nature of Relevant Financial Relationship

    Commercial Interest

    What was received?

    For what role?

    Catherine Friedman, MD, FAPA, DFASAM, Chair

    None

    R. Jeffrey Goldsmith, MD, DLFAPA, DFASAMNone
    Adam J. Gordon, MD, MPH, FACP, DFASAMNone
    Zwaantje Hamming, FNP-C, CARN-APNone

    Herbert L. Malinoff, MD, FACP, DFASAM

    None

    Noel Ilogu, MD, MRCP, DFASAM

    None

    Edwin A. Salsitz, MD, DFASAM

    None

    ASAM Staff and Consultants

    Arlene C. Deverman, MA, CAE, CFRENone

    Marcia Jackson, PhD

    None
    Sandy MetcalfeNone

    ASAM Medical Education Council

    Name

    Nature of Relevant Financial Relationship

    Commercial Interest

    What was received?

    For what role?

    Peter Selby, MBBS, CCFP, FCFP, MHSc, DFASAM, Chair

    Pfizer  Johnson & Johnson Pfizer CanadaGrant funding Consulting Fees Consulting FeesPrincipal  Investigator Consulting Consulting
    Daniel P. Alford, MD, MPH, DFASAMNone
    Michael Fingerhood, MD, FACP, FASAMNone
    Catherine R. Friedman, MD, FAPA, DFASAMNone
    Adam J. Gordon, MD, MPH, FACP, DFASAMNone
    Miriam S. Komaromy, MD, FACP, DFASAMNone
    Edwin A. Salsitz, MD, DFASAMNone
    Mark P. Schwartz, MD, DFASAMNone
    Mark A. Weiner, MD, FASAMNone
    ASAM Staff and Consultants
    Penny S. Mills, MBANone
    Arlene C. Deverman, MA, CAE, CFRENone
    Marcia Jackson, PhDNone
    Dawn C. HowellNone
    Molly S. MazukNone
    Alexandra (Alli) UngerNone
    Jennifer L. ButchartNone


    Learning Objectives

    Module 1

    1. Assess patients for the full spectrum of harmful opioid use including misuse and use disorders
    2. Describe the current epidemiologic trends in opioid misuse including overdose and use disorders
    3. Recall opioid use neurobiology as it applies to the development of an opioid use disorder and relapse risk
    4. Summarize the laws regulating office-based opioid treatment including the Drug Addiction Treatment Act of 2000 and the Comprehensive Addiction and Recovery Act of 2016
    5. Summarize the clinical pharmacology, efficacy and safety of methadone, buprenorphine and naltrexone in treating opioid use disorders

    Module 2

    6. Identify and assess patients who are appropriate for treatment with medications for an opioid use disorder in an office-based setting
    7. Describe procedures for setting up office systems to support medication prescribing for opioid use disorders
    8. Describe procedures for initiating, stabilizing, maintaining, monitoring and modifying treatment of patients on buprenorphine or naltrexone

    Module 3

    9. Summarize the assessment and management of patients with psychiatric and medical co-morbidities associated with opioid use disorders
    10. Describe unique issues of treating adolescents, young adults, pregnant and postpartum patients maintained on medications for opioid use disorders
    11. Summarize acute and chronic pain management strategies for patients with an opioid use disorder

    Overall

    12. Apply for a waiver to prescribe buprenorphine to patients with opioid use disorder

    1. Locate the box on the right that says “View Course" and click “View Course"
      1. A new window will open with the course. Be sure your pop-up blocker is turned off.
    2. Complete Module and Module 4
    3. You will be required to pass all Module CME Quizzes with a grade of 70% or higher
    4. Upon completion of both the 4 live hours and 4 online hours of the course, you will be able to claim CME Credit through the ASAM e-Learning Center



    1. Physicians, Nurse Practitioners, and Physician Assistants who wish to obtain a waiver to prescribe buprenorphine in office based treatment of opioid use disorders.
    2. Clinicians and health care team members working with physicians who prescribe buprenorphine in office based treatment of opioid use disorders.

    The ASAM Treatment of Opioid Use Disorder Course has been made available in part by an unrestricted educational grant from Indivior Inc.


    Apply

    SAMHSA reviews waiver applications within 45 business days of receipt. If approved, you will receive a letter via email that confirms your waiver and includes your prescribing identification number.

    Waiver applications are forwarded to the DEA. DEA regulations require your prescribing identification number to be included on all buprenorphine prescriptions for opioid dependency treatment, along with your regular DEA number.

    If you have not received confirmation of receipt of your application, or if it has been more than 45 business days since submitting it, contact CSAT by email: infobuprenorphine@samhsa.hhs.gov or call 866.287.2728.

    Please ensure that your state regulations allow you to prescribe buprenorphine and other medications to treat OUD before you apply for the waiver.  Some states may have overriding state legislation that will prevent NPs and PAs from prescribing these medications even if Federal law allows it.

    Apply

    SAMHSA reviews waiver applications within 45 business days of receipt. If approved, you will receive a letter via email that confirms your waiver and includes your prescribing identification number.

    Waiver applications are forwarded to the DEA. DEA regulations require your prescribing identification number to be included on all buprenorphine prescriptions for opioid dependency treatment, along with your regular DEA number.

    If you have not received confirmation of receipt of your application, or if it has been more than 45 business days since submitting it, contact CSAT by email: infobuprenorphine@samhsa.hhs.gov or call 866.287.2728.

    Qualify 

    To qualify for a waiver to treat patients with Opioid Use Disorder, NPs and PAs must: 

    • Be licensed under state law to prescribe schedule III, IV, or V medications for pain
    • Complete no less than 24 hours of appropriate education through a qualified provider
    • Through other training or experience, demonstrate the ability to treat and manage OUD
    • If required by state law, supervision or working in collaboration with a qualifying physician to prescribe medications for the treatment of OUD may be required.

    Overview of Legislation

    Physicians

    The Drug Abuse Treatment Act of 2000 (DATA 2000) specifies training is necessary for physicians to obtain a waiver to engage in office‐based treatment of opioid use disorders using drugs approved by the FDA on Schedules III, IV, and V. This course addresses those requirements using a curriculum approved by CSAT/SAMHSA and ASAM, who is one of the national organizations named in the DATA 2000 legislation as eligible to prepare and administer these courses.

    Nurse Practitioners & Physician Assistants

    On July 22, 2016, President Obama signed the Comprehensive Addiction and Recovery Act (CARA) into law. CARA authorizes qualified NPs and PAs to become waivered to prescribe buprenorphine in office-based settings for patients with Opioid Use Disorder (OUD) for a five-year period expiring in October 2021.    

    To qualify, NPs and PAs must: 

    • Be licensed under state law to prescribe schedule III, IV, or V medications for pain  
    • Complete not less than 24 hours of appropriate education through a qualified provider
    • Through other training or experience, demonstrate the ability to treat and manage OUD  
    • If required by state law, be supervised or work in collaboration with a qualifying physician to prescribe medications for the treatment of OUD

    HHS' announcement on November 16, 2016, enables NPs and PAs to immediately begin taking the 24 hours of required training. For the full HHS announcement, click here.

    NPs and PAs can begin the training immediately by taking the 8-hour buprenorphine course ASAM currently offers or that other stakeholders offer (see below for more information). The remaining 16 hours will have to be completed with one training provider. ASAM is developing multiple 16-hour training course options and formats, including collaborations with:

  • Treatment of Opioid Use Disorder: Waiver Qualifying - Akron, OH - Thursday, May 23, 2019

    Product not yet rated Contains 6 Component(s), Medical Credits Offered

    The ASAM Treatment of Opioid Use Disorder Course: Includes Waiver Qualifying Requirements covers all medications and treatments for opioid use disorder, and provides the required education needed to obtain the waiver to prescribe buprenorphine.

    image

        

    image


    Thursday, May 23, 2019 | 8:00 am - 12:00 pm

    Summa Health System – Akron Campus
    Room: ED Auditorium
    525 E. Market St.
    Akron, OH 44304

    Hosted by BrightView and Summa Health

    You can find directions and parking information under the "Handouts" tab

    Welcome to The ASAM Treatment of Opioid Use Disorder Course online access. This course covers all medications and treatments for opioid use disorder, and provides the required education needed to obtain the waiver to prescribe buprenorphine. ASAM is an approved provider by CSAT/SAMHSA of DATA 2000 training.

    This is an 8-hour blended course combining 4 hours of live learning followed by 4 hours of online learning. The online portion of the course builds off the content delivered in the live portion. You must complete both portions to receive credit for the course. 

    Getting started: To begin the online portion of the course, please log-in to your right and locate the box that says "View Course." If you do not know your password, or you have forgotten it, select "Forgot Password" and you will be emailed a link to reset your password. Detailed instructions for completing the online portion of the course can be found under the tab titled Course Instructions.

     If you have any questions, please contact education@ASAM.org.

    CME Information and Disclosure Listing

    Date of Release: July 2015 

    Approved Through: December 2019

    The American Society of Addiction Medicine (ASAM) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. ASAM has been awarded the highest level of Accreditation with Commendation by the ACCME as a provider of continuing medical education.

    The American Society of Addiction Medicine designates this live activity for a maximum of AMA PRA Category 1 Credits. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    The American Society of Addiction Medicine designates this enduring material for a maximum of 4 AMA PRA Category 1 Credits. Physicians should claim only the credit commensurate with the extent of their participation in the activity. 

    This program has been reviewed and is approved for a maximum of 8.00 AAPA Category 1 CME credits by the PA Review Panel. Approval is valid for one year from the issue date of 01/01/2018. Participants may submit the post-test at any time during that period.

    This program was planned in accordance with AAPA's CME Standards for Enduring Material Programs and for Commercial Support of Enduring Material Programs.

    This course has been designated as an approved CME Activity by the American Board of Addiction Medicine (ABAM). Physicians enrolled in the ABAM Maintenance of Certification (MOC) Program can apply a maximum of AMA PRA Category 1 Credit(s) to the CME requirement for Part II: Lifelong Learning and Self-Assessment.

    In accordance with the disclosure policies of ASAM and the ACCME, the effort is made to ensure balance, independence, objectivity, and scientific rigor in all educational activities. These policies include resolving all conflicts of interest between the CME Committee, Planning Committee and faculty, and commercial interests that might otherwise compromise the goal and educational integrity of this activity. All CME Committee, Planning Committee and faculty participating in the activity have disclosed all relevant financial relationships with commercial interests. The CME Committee has reviewed these disclosures and determined that the planning committee and faculty relationships are not inappropriate in the content of their respective presentations and are not inconsistent with the educational goals and integrity of the activity.

    ASAM Treatment of Opioid Use Disorder Course Program Planning Committee

    Name

    Nature of Relevant Financial Relationship

    Commercial Interest

    What was received?

    For what role?

    Dan Alford, MD, MPH, DFASAM, Chair

    None

    Paula J. Lum, MD, MPH, FASAM, Vice Chair

    None

    Edwin Salsitz, MD, DFASAM, Curriculum Director

    None

    Soraya Azari, MD

    None 

    Jill Mattingly, DHSc, MMSc, PA-C

    None

    Debra Newman, PA-C, MPAS, MPH

    None

    Mary McMasters, MD, DFASAMNone

    Yngvild K. Olsen, MD, MPH, DFASAM

    None
    Shawn Ryan, MD, MBA, FASAMAdapt Pharma OrexoConsulting Fee HonorariumContent Expert Speaker
    Kristin Smith, DNP, FNP-C, AAHIVSNone
    Tricia E. Wright, MD, MS, FACOG, FASAMNone

    ASAM CME Committee

    Name

    Nature of Relevant Financial Relationship

    Commercial Interest

    What was received?

    For what role?

    Catherine Friedman, MD, FAPA, DFASAM, Chair

    None

    R. Jeffrey Goldsmith, MD, DLFAPA, DFASAMNone
    Adam J. Gordon, MD, MPH, FACP, DFASAMNone
    Zwaantje Hamming, FNP-C, CARN-APNone

    Herbert L. Malinoff, MD, FACP, DFASAM

    None

    Noel Ilogu, MD, MRCP, DFASAM

    None

    Edwin A. Salsitz, MD, DFASAM

    None

    ASAM Staff and Consultants

    Arlene C. Deverman, MA, CAE, CFRENone

    Marcia Jackson, PhD

    None
    Sandy MetcalfeNone

    ASAM Medical Education Council

    Name

    Nature of Relevant Financial Relationship

    Commercial Interest

    What was received?

    For what role?

    Peter Selby, MBBS, CCFP, FCFP, MHSc, DFASAM, Chair

    Pfizer  Johnson & Johnson Pfizer CanadaGrant funding Consulting Fees Consulting FeesPrincipal  Investigator Consulting Consulting
    Daniel P. Alford, MD, MPH, DFASAMNone
    Michael Fingerhood, MD, FACP, FASAMNone
    Catherine R. Friedman, MD, FAPA, DFASAMNone
    Adam J. Gordon, MD, MPH, FACP, DFASAMNone
    Miriam S. Komaromy, MD, FACP, DFASAMNone
    Edwin A. Salsitz, MD, DFASAMNone
    Mark P. Schwartz, MD, DFASAMNone
    Mark A. Weiner, MD, FASAMNone
    ASAM Staff and Consultants
    Penny S. Mills, MBANone
    Arlene C. Deverman, MA, CAE, CFRENone
    Marcia Jackson, PhDNone
    Dawn C. HowellNone
    Molly S. MazukNone
    Alexandra (Alli) UngerNone
    Jennifer L. ButchartNone


    Learning Objectives

    Module 1

    1. Assess patients for the full spectrum of harmful opioid use including misuse and use disorders
    2. Describe the current epidemiologic trends in opioid misuse including overdose and use disorders
    3. Recall opioid use neurobiology as it applies to the development of an opioid use disorder and relapse risk
    4. Summarize the laws regulating office-based opioid treatment including the Drug Addiction Treatment Act of 2000 and the Comprehensive Addiction and Recovery Act of 2016
    5. Summarize the clinical pharmacology, efficacy and safety of methadone, buprenorphine and naltrexone in treating opioid use disorders

    Module 2

    6. Identify and assess patients who are appropriate for treatment with medications for an opioid use disorder in an office-based setting
    7. Describe procedures for setting up office systems to support medication prescribing for opioid use disorders
    8. Describe procedures for initiating, stabilizing, maintaining, monitoring and modifying treatment of patients on buprenorphine or naltrexone

    Module 3

    9. Summarize the assessment and management of patients with psychiatric and medical co-morbidities associated with opioid use disorders
    10. Describe unique issues of treating adolescents, young adults, pregnant and postpartum patients maintained on medications for opioid use disorders
    11. Summarize acute and chronic pain management strategies for patients with an opioid use disorder

    Overall

    12. Apply for a waiver to prescribe buprenorphine to patients with opioid use disorder

    1. Locate the box on the right that says “View Course" and click “View Course"
      1. A new window will open with the course. Be sure your pop-up blocker is turned off.
    2. Complete Module and Module 4
    3. You will be required to pass all Module CME Quizzes with a grade of 70% or higher
    4. Upon completion of both the 4 live hours and 4 online hours of the course, you will be able to claim CME Credit through the ASAM e-Learning Center



    1. Physicians, Nurse Practitioners, and Physician Assistants who wish to obtain a waiver to prescribe buprenorphine in office based treatment of opioid use disorders.
    2. Clinicians and health care team members working with physicians who prescribe buprenorphine in office based treatment of opioid use disorders.

    The ASAM Treatment of Opioid Use Disorder Course has been made available in part by an unrestricted educational grant from Indivior Inc.


    Apply

    SAMHSA reviews waiver applications within 45 business days of receipt. If approved, you will receive a letter via email that confirms your waiver and includes your prescribing identification number.

    Waiver applications are forwarded to the DEA. DEA regulations require your prescribing identification number to be included on all buprenorphine prescriptions for opioid dependency treatment, along with your regular DEA number.

    If you have not received confirmation of receipt of your application, or if it has been more than 45 business days since submitting it, contact CSAT by email: infobuprenorphine@samhsa.hhs.gov or call 866.287.2728.

    Please ensure that your state regulations allow you to prescribe buprenorphine and other medications to treat OUD before you apply for the waiver.  Some states may have overriding state legislation that will prevent NPs and PAs from prescribing these medications even if Federal law allows it.

    Apply

    SAMHSA reviews waiver applications within 45 business days of receipt. If approved, you will receive a letter via email that confirms your waiver and includes your prescribing identification number.

    Waiver applications are forwarded to the DEA. DEA regulations require your prescribing identification number to be included on all buprenorphine prescriptions for opioid dependency treatment, along with your regular DEA number.

    If you have not received confirmation of receipt of your application, or if it has been more than 45 business days since submitting it, contact CSAT by email: infobuprenorphine@samhsa.hhs.gov or call 866.287.2728.

    Qualify 

    To qualify for a waiver to treat patients with Opioid Use Disorder, NPs and PAs must: 

    • Be licensed under state law to prescribe schedule III, IV, or V medications for pain
    • Complete no less than 24 hours of appropriate education through a qualified provider
    • Through other training or experience, demonstrate the ability to treat and manage OUD
    • If required by state law, supervision or working in collaboration with a qualifying physician to prescribe medications for the treatment of OUD may be required.

    Overview of Legislation

    Physicians

    The Drug Abuse Treatment Act of 2000 (DATA 2000) specifies training is necessary for physicians to obtain a waiver to engage in office‐based treatment of opioid use disorders using drugs approved by the FDA on Schedules III, IV, and V. This course addresses those requirements using a curriculum approved by CSAT/SAMHSA and ASAM, who is one of the national organizations named in the DATA 2000 legislation as eligible to prepare and administer these courses.

    Nurse Practitioners & Physician Assistants

    On July 22, 2016, President Obama signed the Comprehensive Addiction and Recovery Act (CARA) into law. CARA authorizes qualified NPs and PAs to become waivered to prescribe buprenorphine in office-based settings for patients with Opioid Use Disorder (OUD) for a five-year period expiring in October 2021.    

    To qualify, NPs and PAs must: 

    • Be licensed under state law to prescribe schedule III, IV, or V medications for pain  
    • Complete not less than 24 hours of appropriate education through a qualified provider
    • Through other training or experience, demonstrate the ability to treat and manage OUD  
    • If required by state law, be supervised or work in collaboration with a qualifying physician to prescribe medications for the treatment of OUD

    HHS' announcement on November 16, 2016, enables NPs and PAs to immediately begin taking the 24 hours of required training. For the full HHS announcement, click here.

    NPs and PAs can begin the training immediately by taking the 8-hour buprenorphine course ASAM currently offers or that other stakeholders offer (see below for more information). The remaining 16 hours will have to be completed with one training provider. ASAM is developing multiple 16-hour training course options and formats, including collaborations with:

  • Webinar: The ASAM Criteria Copyright and Permissions Process for States

    Contains 1 Component(s)

    In this free webinar, learn about the ASAM Criteria copyright and permissions process for states.

    Webinar Overview

    In Spring 2019, The ASAM Criteria copyright and permissions process was updated to include agreements to enable public entities, providers, and other stakeholders to reference their use of The ASAM Criteria. The changes are part of a range of programs designed to support effective implementation of The ASAM Criteria and protect ASAM’s intellectual property from misuse. These programs include an ASAM Level of Care certification program delivered by CARF, a robust training program on The ASAM Criteria, and ongoing enhancements to the ASAM CONTINUUM software – a clinical decision support tool used to assist in treatment planning for individuals with addiction. All of these initiatives have the end goals of protecting patients and preserving the credibility of providers accurately implementing the evidence-based standards found in The ASAM Criteria.

    Margaret A.E. Jarvis

    MD, DFASAM

    Margaret Jarvis finished her medical school, psychiatry residency and Addiction Medicine Fellowship at the Medical College of Virginia in Richmond. She is board certified and recertified in psychiatry with the CAQ in Addiction Psychiatry. She was ASAM certified (now ABAM certified). She has been a member of ASAM since the early 90’s and became a Fellow of the Society in 2003. She has served on the Board of Directors for one term and currently is the co-chair of the Ruth Fox Planning; and a member of the Finance Committee and the Constitution and Bylaws Committee. She has also worked on Examination Committee for ASAM and now ABAM since 2000.

    Dr. Jarvis is the Medical Director at Marworth, in Waverly, PA, which is the residential addiction treatment center for the Geisinger Health System. She has been in this position since 1999. She is also Clinical Assistant Professor of Psychiatry at the Penn State University College of Medicine in Hershey, PA.

    Dr. Jarvis is a member of the Society for the Advancement of Sexual Health, a professional organization of therapists who treat sexual addiction, and served on that board of directors from 2001-2006, as president from 2004-2006. She received the Merit award from SASH in 2011. Dr. Jarvis currently serves as the Treasurer of the Board of Marley’s Mission, a non-profit that provides equine-assisted psychotherapy to abused children in the Scranton, PA area.

  • Webinar: The ASAM Criteria Copyright and Permissions Process for Providers

    Contains 1 Component(s)

    In this free webinar, learn about the ASAM Criteria copyright and permissions process for providers.

    Webinar Overview

    In Spring 2019, The ASAM Criteria copyright and permissions process was updated to include agreements to enable public entities, providers, and other stakeholders to reference their use of The ASAM Criteria. The changes are part of a range of programs designed to support effective implementation of The ASAM Criteria and protect ASAM’s intellectual property from misuse. These programs include an ASAM Level of Care certification program delivered by CARF, a robust training program on The ASAM Criteria, and ongoing enhancements to the ASAM CONTINUUM software – a clinical decision support tool used to assist in treatment planning for individuals with addiction. All of these initiatives have the end goals of protecting patients and preserving the credibility of providers accurately implementing the evidence-based standards found in The ASAM Criteria.

    Margaret A.E. Jarvis

    MD, DFASAM

    Margaret Jarvis finished her medical school, psychiatry residency and Addiction Medicine Fellowship at the Medical College of Virginia in Richmond. She is board certified and recertified in psychiatry with the CAQ in Addiction Psychiatry. She was ASAM certified (now ABAM certified). She has been a member of ASAM since the early 90’s and became a Fellow of the Society in 2003. She has served on the Board of Directors for one term and currently is the co-chair of the Ruth Fox Planning; and a member of the Finance Committee and the Constitution and Bylaws Committee. She has also worked on Examination Committee for ASAM and now ABAM since 2000.

    Dr. Jarvis is the Medical Director at Marworth, in Waverly, PA, which is the residential addiction treatment center for the Geisinger Health System. She has been in this position since 1999. She is also Clinical Assistant Professor of Psychiatry at the Penn State University College of Medicine in Hershey, PA.

    Dr. Jarvis is a member of the Society for the Advancement of Sexual Health, a professional organization of therapists who treat sexual addiction, and served on that board of directors from 2001-2006, as president from 2004-2006. She received the Merit award from SASH in 2011. Dr. Jarvis currently serves as the Treasurer of the Board of Marley’s Mission, a non-profit that provides equine-assisted psychotherapy to abused children in the Scranton, PA area.

  • Webinar: What is ASAM Level of Care Certification?

    Product not yet rated Contains 1 Component(s)

    In this free webinar, learn about the ASAM Level of Care certification and the pilot process that was used to ensure its validity.

    Webinar Overview

    This webinar provides an overview of ASAM Level of Care certification and the pilot process that was used to ensure its validity. ASAM Level of Care certification, delivered in partnership with CARF International, is the first program of its kind to independently assess and verify treatment programs’ ability to deliver services consistent with the levels of care described in The ASAM Criteria. It will initially cover adult residential programs at Levels 3.1, 3.5, and 3.7 of The ASAM Criteria. The certification demonstrates a program’s capacity to deliver a specific level of care, thereby differentiating between the many levels of care available for addiction treatment.

    Paul H. Earley

    MD, DFASAM

    Dr. Earley has worked in Addiction Medicine for over 30 years. He treats all types of addictive disorders and specializes in the assessment, treatment and management of health care professionals. As a therapist, he works with patients already in recovery, providing long term therapy for those who suffer from this disease. His professional expertise extends to advocacy for professionals before agencies and licensing boards. 

    Dr. Earley is a dynamic speaker and educator; he speaks and trains on topics of addiction, its treatment and addiction among health care professionals. In addition, he trains therapists about the neurobiological basis of psychotherapy. In his travels, he has provided training in the United States, Canada, the United Kingdom, Italy, Iceland and Switzerland.

    He is the author of two books and several research articles on addiction and its treatment. His most recent book, RecoveryMind Training is an innovative and comprehensive process designed to reengineer addiction treatment. He is a contributing author to the American Society of Addiction Medicine (ASAM) Textbook: Principles of Addiction Medicine, as author of the chapter: Physician Health Programs and Addiction among Physicians. He is a contributing author to the ASAM Criteria. His work was featured in the documentary series on addiction entitled Close to Home by Bill Moyers.

    Currently, Dr. Earley is the Medical Director of the Georgia Professionals Health Program, Inc., the Physicians Health Program (PHP) for the state of Georgia and the President-elect of the Federation of State Physician Health Programs (FSPHP). Dr. Earley is the current president-elect of the American Society of Addiction Medicine (ASAM). He is a Distinguished Fellow of ASAM and has served on the board of ASAM for over 14 years in several capacities.

    Michael W. Johnson

    MA, CAP

    Michael joined CARF as managing director of the Behavioral Health accreditation area in 2013. A certified addictions professional, Michael has more than 30 years of experience as a clinician, manager, and executive working in mental health, substance abuse, and intellectual disabilities. He was a CARF surveyor for 16 years and holds a master's degree in communications from the University of Central Florida.